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PHeart Rhythm Disorders
Recurrent Unexplained Palpitations (RUP) Study
Comparison of Implantable Loop
Recorder Versus Conventional Diagnostic Strategy
Franco Giada, MD,* Michele Gulizia, MD,† Maura Francese, MD,† Francesco Croci, MD,‡
Lucio Santangelo, MD,§ Maurizio Santomauro, MD, Eraldo Occhetta, MD,¶ Carlo Menozzi, MD,#
Antonio Raviele, MD*
Venice, Catania, Lavagna, Naples, Novara, and Reggio Emilia, Italy
Objectives The aim of the study was to compare the diagnostic yield and the costs of implantable loop recorder (ILR) with
those of the conventional strategy in patients with unexplained palpitations.
Background In patients with unexplained palpitations, especially in those with infrequent symptoms, the conventional strat-
egy, including short-term ambulatory electrocardiogram (ECG) monitoring and electrophysiological study, some-
times fails to establish a diagnosis.
Methods We studied 50 patients with infrequent (1 episode/month), sustained (1 min) palpitations. Before enroll-
ment, patients had a negative initial evaluation, including history, physical examination, and ECG. Patients were
randomized either to conventional strategy (24-h Holter recording, a 4-week period of ambulatory ECG monitor-
ing with an external recorder, and electrophysiological study) (n  24) or to ILR implantation with 1-year moni-
toring (n  26). Hospital costs of the 2 strategies were calculated.
Results A diagnosis was obtained in 5 patients in the conventional strategy group, and in 19 subjects in the ILR group
(21% vs. 73%, p  0.001). Despite the higher initial cost, the cost per diagnosis in the ILR group was lower than
in the conventional strategy group (€3,056  €363 vs. €6,768  €6,672, p  0.012).
Conclusions In subjects without severe heart disease and with infrequent palpitations, ILR is a safe and more cost-effective
diagnostic approach than conventional strategy. (J Am Coll Cardiol 2007;49:1951–6) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.036t
a
a
p
M
S
r
t
e
C
c
w
b
w
P
tJournal Club 
Selection
www.jaccjc.org
In subjects with palpitations that remain
unexplained after initial evaluation (history,
physical examination, and electrocardiogram
[ECG]), conventional diagnostic strategy in-
cludes short-term ambulatory ECG monitor-
ing by means of 24-h Holter recording and
xternal recorders (ERs), and electrophysiological study
EPS) (1– 4). However, despite all these investigations, it
s sometimes difficult to establish a diagnosis, especially
n patients with infrequent symptoms (4).
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he #Division of Cardiology, Reggio Emilia, Reggio Emilia, Italy. This study was
unded, in part, by Medtronic.o
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007, accepted February 5, 2007.Implantable loop recorders (ILRs) could prove useful in
he study of palpitations (1), but no data are currently
vailable regarding their diagnostic yield in this setting.
The aim of this trial was to compare the diagnostic yield
nd costs of ILR with those of the conventional strategy, in
atients with infrequent unexplained palpitations.
ethods
tudy design. This trial was a multicenter, prospective,
andomized study. The primary end point was to establish
he cause of the palpitations. Patients were randomized
ither to conventional strategy or to ILR implantation.
rossover was not mandated by the study protocol, but if
onventional strategy did not provide a diagnosis, patients
ere invited to cross over to ILR. The study was approved
y the ethics committee of each center, and all patients gave
ritten, informed consent.
atient eligibility. Consecutive patients referred for palpi-
ations (defined as an unpleasant sensation of the awareness
f the heart beat) as their chief complaint underwent an
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Cost-Effectiveness Analysis of Palpitations Management May 15, 2007:1951–6initial evaluation including his-
tory, physical examination, and
ECG. Patients also underwent
echocardiography in order to ex-
clude severe structural heart dis-
ease (SHD), and blood chemistry
examinations in order to exclude
palpitations of noncardiac origin,
according to the criteria of We-
ber and Kapoor (4).
Subjects with evident extra-
systolic or anxiety-based palpita-
tions were not enrolled. We ex-
cluded patients with severe SHD
or hereditary arrhythmogenic
syndrome, because of concerns of
the potential risk of sudden death
during recurrence of palpitations.
Patients were enrolled if they
had a negative initial evaluation,
o apparent or only mild heart disease (ejection fraction
35%), and sustained (1 min), infrequent (1 episode/
onth), and clinically significant (associated to presyncope,
iaphoresis, chest pain, and asthenia) palpitations.
onventional strategy. The conventional strategy com-
rised 24-h Holter recording, a 4-week period of ambula-
ory ECG monitoring with an ER, and EPS, when the 2
revious examinations yielded negative results, on a day case
asis. Monitoring was regarded as diagnostic only when
symptom-rhythm correlation was established during
pontaneous palpitations (1,5). Electrophysiological study,
erformed in accordance with standard procedures, was
egarded as diagnostic if it induced any brady- or tachyar-
hythmias that were sustained (1 min or requiring urgent
nterruption), and accompanied by reproduction of the
pontaneous symptoms (2,6).
LR. Patients underwent ILR implantation (Reveal Plus,
edtronic Inc., Minneapolis, Minnesota) on a day case
asis, and were monitored for at least 12 months. Implant-
Abbreviations
and Acronyms
AF  atrial fibrillation
AVB  atrioventricular
block
EPS  electrophysiological
study
ER  external recorder
ICER  incremental cost-
effectiveness ratio
ILR  implantable loop
recorder
SB  sinus bradycardia
SHD  structural heart
disease
ST  sinus tachycardia
SVT  supraventricular
tachycardia
esource Consumption and Cost Calculations for Testing
Table 1 Resource Consumption and Cost Calculations for Test
Staff Main Equipme
Holter monitoring
Consumption, n 1 physician, 1 nurse 1 recorder, 1 battery, 7 elec
Cost, € 40
External recorder
Consumption, n 1 physician, 1 nurse 1 recorder, 15 batteries, 45
Cost, € 53
EPS
Consumption, n 1 physician, 1 nurse 2 catheters, 2 introducers,
Cost, € 185
ILR†
Consumption, n 1 physician, 1 nurse 1 device, 10 electrodes
Cost, € 205Including hospital overheads; †implantation and removal procedure.
EPS  electrophysiological study; ILR  implantable loop recorder; €  2005 Euro.ble loop recorder monitoring was regarded as diagnostic
nly when a symptom-rhythm correlation was established
uring spontaneous palpitations resembling the symptoms
efore enrollment (1,5). Implantable loop recorder moni-
oring was regarded as nondiagnostic when arrhythmias
ere not associated to any symptoms.
ost assessment. The perspective was that of the hospital.
he third payer, patients, and societal costs were not evaluated.
or each investigation, the items that were considered are
resented in Table 1. The incremental cost-effectiveness ratio
ICER) was calculated as the difference between the total cost
f ILR and conventional strategy, divided by the difference in
he percentage of diagnoses made between ILR and conven-
ional strategy. To evaluate the economic impact of the various
nvestigations, a sensitivity analysis was performed.
tatistical analysis. Differences between strategies were
ested by means of Student t test for unpaired data,
ilcoxon rank sum test, and Fisher exact test, as requested.
value of p  0.05 was considered significant.
ample size. In patients with infrequent palpitations, we
ypothesised that ILR was superior to conventional strat-
gy, and we estimated a diagnostic yield of 75% and 45%,
espectively. The resulting sample size was 25 patients for
ach group.
esults
atient characteristics. Fifty patients with unexplained
alpitations were randomized: 24 to the conventional strat-
gy group and 26 to the ILR group. There were no
ifferences in baseline clinical characteristics between
roups (Table 2). A diagnosis was obtained in 30 of the 50
atients (60%) (Fig. 1); in 22 of these 30 (73%), a significant
rrhythmia was diagnosed (Table 3). No adverse events
ere observed, and there were no facility visits other than
hose planned in the study protocol.
rimary end point. In the conventional strategy group, a
iagnosis was obtained in 5 (21%) patients (mean time to
iagnosis 36 26 days). Holter monitoring proved negative
Disposables Electrophysiology Room* Total Cost
0 —
0 43
odes 0 —
0 88
rillation pads, 5 electrodes 120 min —
310 2,262
180 min —
464 2,360ing
nt and
trodes
3
electr
35
2 defib
1,767
1,690
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May 15, 2007:1951–6 Cost-Effectiveness Analysis of Palpitations Managementn all patients. During monitoring with ER (mean duration
0 25 days), atrial fibrillation (AF) was recorded in 1 case
nd supraventricular tachycardia (SVT) in 1 case, palpita-
ions did not recur in 16 patients, 5 patients failed to activate
he device during an episode of palpitations, and there was
case of device malfunction. Electrophysiological study
nduced SVT in 3 cases. Three of the 4 patients with SVT
nderwent successful ablation of their arrhythmias, while
Baseline Clinical Characteristics of the Patients
Table 2 Baseline Clinical Characteristics of
Age, yrs (mean  SD)
Female gender, n (%)
Palpitation episodes in the last year, n (median, IQR)
Length of episodes, min (median, IQR)
Duration of symptoms, months (median, IQR)
Palpitations with associated symptoms, n (%)
Presyncope
Diaphoresis
Chest pain
Asthenia
Abnormal electrocardiogram, n (%)
Right bundle branch block
Abnormalities of ventricular repolarization
Structural heart disease, n (%)
Hypertension
Valvular heart disease
Ischemic heart disease
Dilated cardiomyopathy
LVEF, % (mean  SD)
IQR  interquartile range; LVEF  left ventricular ejection fraction.Figure 1 Flow Diagram of Diagnostic Outcomehe other 1, together with the patient with AF, received
ntiarrhythmic drugs.
In the ILR group, a diagnosis was obtained in 19 (73%)
ubjects (mean time to diagnosis 279 228 days). Thus, the
iagnostic yield of ILR was significantly higher with respect
o conventional strategy (73% vs. 21%, p  0.001). During
onitoring (mean duration 321  235 days), ILR recorded
VT in 6 cases (Fig. 2), AF in 4 cases, atrial flutter in 2
ied
atients Studied
Conventional
Diagnostic Strategy
(n  24)
Implantable
Loop Recorder
(n  26)
43 17 51 18
19 (79) 14 (54)
6 (4–10) 8 (3–10)
40 (5–72) 51 (8–67)
30 (15–66) 44 (15–100)
24 (100) 26 (100)
16 17
7 6
5 6
8 10
4 (17) 4 (15)
1 2
3 2
6 (25) 11 (42)
5 7
3
1
1
63 6 60 7Stud
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Cost-Effectiveness Analysis of Palpitations Management May 15, 2007:1951–6ases, sinus tachycardia (ST) (100 beats/min) in 4 cases,
inus bradycardia (SB) (40 beats/min) in 2 cases, and
aroxysmal atrioventricular block (AVB) in 1 case. Palpita-
ions did not recur in 6 patients; 1 patient failed to activate
he device during an episode of palpitations. The automatic
etection mode was activated, but no significant arrhyth-
ias were recorded because the memory of the devices was
lways saturated by inappropriate activations.
iagnostic Outcome
Table 3 Diagnostic Outcome
Conventional
Diagnostic Strategy
(n  24)
Implantable
Loop Recorder
(n  26)
Diagnosis, n (%) 5 (21) 19 (73)*
Supraventricular tachycardia 4 6
Atrial fibrillation/atrial flutter 1 6
Sinus tachycardia 0 4
Sinus bradycardia 0 2
Paroxysmal AV block 0 1
No diagnosis, n (%) 19 (79) 7 (27)
No palpitation recurrence during
monitoring
16 6
Patient error in activating the recorder 5 1
Recorder malfunctioning 1 0
Negative EPS 19 —
p  0.001.
AV  atrioventricular; EPS  electrophysiological study.Figure 2 Supraventricular Tachycardia Recorded From Implantable LooOf the 6 patients with SVT, 4 underwent successful
blation of their arrhythmias, while the other 2 received
ntiarrhythmic drugs. Patients with AF or flutter were
reated with antiarrhythmic drugs, those with ST received
nxiolytic therapy, and those with SB and AVB underwent
acemaker implantation.
osts. The mean cost per patient was significantly higher,
hile the mean cost per diagnosis was significantly lower in
he ILR group than in the conventional strategy group. The
CER for the ILR strategy was €1,576. Sensitivity analysis
onfirms the results, except for EPS 50% (Table 4).
rossover. Nine of the 19 patients in whom conventional
trategy proved negative consented to crossover ILR. A
iagnosis was obtained in 6 (67%) (mean time to diagnosis
16 226 days). During monitoring (mean duration 326
36 days), ILR recorded SVT in 1 case, ST in 4 cases, and
aroxysmal AVB in 1 case, while symptoms did not recur in
patients. The patient with SVT underwent ablation, the 4
ubjects with ST received anxiolytic therapy, and the patient
ith AVB underwent pacemaker implantation.
ollow-up. After a diagnosis was reached, patients were
ollowed up for at least 12 months (mean duration 334 
10 days). Palpitations were completely eliminated in 22
atients with arrhythmic diagnosis treated with ablation,
acemaker, or drugs, while they were considerably reduced
from a median number of 9 episodes/year before enroll-p Recorder During an Episode of Palpitations
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May 15, 2007:1951–6 Cost-Effectiveness Analysis of Palpitations Managementent, to 1.4 episodes/year) in 8 patients with nonarrhyth-
ic diagnosis who received anxiolytic therapy.
iscussion
ain findings. This study shows that, in patients with
nfrequent symptoms and without severe SHD, the diagnostic
ield of conventional strategy is low, and that ILR is more
ikely to provide a diagnosis. Moreover, ILR explained the
ikely nature of palpitations in most of the patients with
egative conventional strategy who consented to crossover to
rolonged monitoring strategy. Similar observations have been
ade by Krahn et al. (7,8) on evaluating patients with syncope.
n patients with arrhythmic diagnosis, the prescribed treatment
ompletely eliminated symptoms, thus confirming that the
ssigned diagnoses really represented the cause of palpitations.
The ILR yielded more diagnoses than conventional strategy,
esulting in greater cost-effectiveness. Moreover, the ICER for
he ILR strategy was low in relation to the costs of further
nvestigations, which are necessary when the diagnoses are
ewer. However, if only 50% of patients had undergone EPS,
proportion close to common clinical practice, the cost per
iagnosis of conventional strategy would no longer have proved
ignificantly higher than that of ILR. These data confirm that
PS constituted the main driver of cost, and that it is not
ost-effective in patients without SHD (2).
The low diagnostic value of conventional strategy found
n our study, however, does not negate the role of conven-
ional diagnostic testing. Indeed, both ILR and conven-
ional strategy have advantages and disadvantages, and may
e considered complementary.
Our results may be influenced by the infrequency of
ymptoms, the absence of severe SHD, and the relatively
oung age of our patients. Indeed, the diagnostic values of
R and EPS mainly depend on the frequency of palpita-
ions and the presence of SHD, respectively (1–3,5,6).
oreover, older patients are frequently unable to use ER
roperly (3,5,6). Thus, the baseline characteristics of the
opulation are critical to predicting the diagnostic value of
ost of Testing and Sensitivity Analysis
Table 4 Cost of Testing and Sensitivity Analysis
Cost Per Patient
Conventional
Diagnostic Strategy
(n  24)
Implantable
Loop Recorde
(n  26)
Cost of testing, € (mean  SD) 1,410 1,389 2,233 265
Sensitivity analysis, € (mean  SD)
Holter monitoring, 75% 1,399 1,394 2,233 265
Holter monitoring, 50% 1,389 1,389 2,233 265
External recorder, 75% 1,388 1,399 2,233 265
External recorder, 50% 1,366 1,388 2,233 265
EPS, 75% 1,253 1,403 2,233 265
EPS, 50% 1,065 1,412 2,233 265
CER  incremental cost-effectiveness ratio for implantable loop recorder; other abbreviations ashe investigations. winor findings. Most patients with palpitations are found
o have premature beats, ST, SVT, and AF, while ventric-
lar tachycardia is much less common, and is typical of
atients with severe SHD (3). Our results are in line with
he aforementioned observations. Indeed, as patients with
xtra-systolic palpitations and severe SHD were not en-
olled, we found a high prevalence of SVT and AF, but no
remature beats or ventricular tachyarrhythmias. However,
he fairly high percentage of ST during symptoms in our
atients suggests that initial evaluation often fails to indi-
iduate patients with anxiety-based palpitations.
Many subjects are not able to use ER properly (3,5). Indeed,
n this study, 6 of 24 patients (25%) proved unable to use ER
orrectly, while only 1 of 25 patients (4%) was unable to
ctivate ILR. The inclusion of presumptive diagnostic catego-
ies based on the auto-activation feature of the new generation
mbulatory ECG recorders could offer the advantage of over-
oming the inability of some patients to activate the devices
ppropriately, further increasing the diagnostic yield of moni-
oring (9). However, the auto-activation mode did not prove to
e useful in the present study.
tudy limitations. As our study population included a
roup of highly selected patients, these results cannot be
eneralized to the entire population with palpitations, par-
icularly those with frequent symptoms, who may benefit
rom ER, and those with severe SHD, in which EPS plays
much greater diagnostic role. Moreover, in the majority of
atients, palpitations are a well-tolerated and benign con-
ition, and initial evaluation is sufficient to yield a diagnosis
r to exclude major arrhythmic disorders. Therefore, further
nvestigations should be considered only in patients with
HD and in those with associated symptoms in which
alpitations can be due to important arrhythmias, and prove
ery troublesome (1–4).
Given the possible placebo effect of invasive procedures,
he open-label structure of the study may be considered a
imitation. Indeed, probably as a consequence of a placebo
ffect of the surgical procedure, the mean time interval to
he first palpitation recurrence during monitoring with ILR
Cost Per Diagnosis
p Value
Conventional
Diagnostic Strategy
(n  24)
Implantable
Loop Recorder
(n  26) p Value ICER
0.001 6,768 6,672 3,056 363 0.012 1,576
0.008 6,716 6,690 3,056 363 0.013 1,596
0.007 6,665 6,665 3,056 363 0.014 1,617
0.008 6,662 6,713 3,056 363 0.015 1,618
0.006 6,556 6,663 3,056 363 0.017 1,660
0.003 6,014 6,735 3,056 363 0.042 1,876
0.001 5,110 6,777 3,056 363 0.151 2,237
e 1.ras higher than expected, taking into account the mean
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Cost-Effectiveness Analysis of Palpitations Management May 15, 2007:1951–6ime interval between each episode of palpitation in the year
efore ILR implantation (279 vs. 52 days).
onclusions
his study demonstrates that, in subjects with infrequent
nexplained palpitations and without severe SHD, ILR is a
afe and cost-effective diagnostic approach. Thus, ILR may
e a useful primary strategy in these patients, and in those
ho are poorly compliant with other recording devices. In
articular, ILR should be offered to patients with persistent
ymptoms that suggest an arrhythmic cause, when conven-
ional testing fails to yield a diagnosis.
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